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ABSTRACT 
Resting heart rate is a heritable trait correlated with lifespan. Little is known 
about the genetic contribution of resting heart rate and its relationship with 
mortality. We performed a genome-wide association discovery and replication 
analysis starting with 19.9 million genetic variants and studying up to 265,046 
individuals to identify 64 loci associated with resting heart rate (P<5×10-8), 46 
of these were novel. We then used the identified genetic variants as an 
instrument to study the association between resting heart rate and all-cause 
mortality. We observed that a genetically predicted resting heart rate of 5 beats 
per minute was associated with a 20% increased mortality risk (hazard ratio 
1.20, 95% CI of 1.11-1.28, P=8.20×10-7) translating to a 2.9 years reduction in 
life expectancy for males and 2.6 years for females. Our findings provide novel 
evidence for shared genetic predictors of resting heart rate and all-cause 
mortality.  
Among mammals, there exists an inverse semi-logarithmic relation between resting 
heart rate and life expectancy with only the human species deviating from this line1,2. 
In humans, resting heart rate is a well-established predictor of overall mortality in the 
general population3-8, as well as in patients with hypertension9, coronary artery 
disease (CAD)10, and heart failure11. The association of heart rate with life 
expectancy or risk does not provide sufficient evidence for a shared or causal 
relationship. Heart rate is regulated by complex interactions of biological systems, 
including the autonomous nervous and hormonal systems12. In addition, resting heart 
rate is associated with many other cardiovascular risk factors, including blood 
pressure, smoking, glucose metabolism, lipids, C-reactive protein, metabolic 
syndrome, body mass index, and diabetes mellitus13-16. In some conditions, including 
heart failure, reduction of heart rate has been directly demonstrated to lead to event 
reduction providing evidence that heart rate is indeed a modifiable causal risk factor 
and not just a risk marker or a reflection of comorbidities11. However, in patients with 
CAD and hypertension, β-adrenergic receptor-blocking agent (beta-blockers) were 
not associated with lower risk of cardiovascular events beyond its effect on blood 
pressure17,18, in patients with permanent atrial fibrillation, lenient rate control is as 
effective as strict rate control19, and heart rate reduction with ivabradine did not 
improve outcomes in patients with CAD20 but in patients with heart failure it did21. A 
mechanistic explanation linking higher resting heart rate with increased mortality 
remains enigmatic. To further our knowledge on genes influencing resting heart rate 
we performed a genome-wide association study on 134,251 participants from UK 
Biobank22 and replicated our findings in 130,795 additional individuals. Using the 
identified genetic variants as instrumental variables we explored the relationship 
between resting heart rate with cardiovascular risk factors, comorbidities and fatal 
and non-fatal outcomes. Bioinformatic analyses of associated variants were also 
undertaken to identify potential biological pathways and mechanisms. 
We studied 134,251 individuals participating in UK Biobank. The average age was 
56.6 years (interquartile range [IQR] 50 to 63), and 47.2% of the participants were 
male. Baseline characteristics are presented in Table 1 and Supplementary Table 
1. The median duration of follow-up for mortality was 4.9 years (IQR 4.3 to 5.5 years)  
and there were 2,364 mortality events in total. Incidence rate 3.6 events (95% CI 3.4 
to 3.7 events) per 1000 person-years of follow-up.  
In UK Biobank we identified genetic variants at 76 loci associated with resting heart 
rate at P<5×10-8 (Figure 1, Table 2, Supplementary Table 2, Supplementary 
Figures 1-3). 64 of these loci replicated in 130,795 individuals derived from 4 
cohorts and 46 loci were novel23. The genetic variants at the 64 loci were well 
imputed with an info >0.9 except one (rs11183443) which had an information 
measure of 0.30. At 11 loci we found evidence for multiple independent associations 
with resting heart rate in conditional analyses (Supplementary Table 3). As 
expected, the magnitudes of the associations were small and ranged from 0.2 to 1.1 
bpm per effect allele. Collectively, the total variance explained by the 64 loci for 
resting heart rate was 2.5%.  
 
We studied the potential modifying effect of gender, beta-blockers and calcium-
channel blockers on the association of genetic variants on resting heart rate but did 
not observe any significant interactions (Supplementary Table 4).  
 
We summed the number of resting heart rate increasing alleles weighted for the 
strength of the association in the replication dataset to create a weighted GRS for 
each individual, and evaluated associations with cardiovascular measures. 
Genetically determined higher resting heart rate was associated with higher body-
mass index, systolic and diastolic blood pressure and higher odds of having 
hypertension, active smoking behavior, experiencing supraventricular tachycardias, 
and lower odds of device implantation (all P<0.05; Table 3). Shared heritability 
estimates are presented in Supplementary Table 5 and indicate correlations of 
resting heart rate with body-mass index, blood pressure, hypertension, diabetes, 
active smoking behavior, and myocardial infarction. 
 
In a random-effects meta-analysis of the genetic variant-specific β3 (the putative 
association between resting heart rate and outcome mediated through that variant) 
of all hypothesis generating loci (P<1×10−5) we observed a significant association 
between genetic variants associated with resting heart rate and all-cause mortality 
translating to a relative increase of 20%) in all-cause mortality risk per 5 bpm 
increase of resting heart rate (Table 4, Supplementary Figure 4). When restricting 
the number of genetic variants stepwise from P<1×10−5 to P<5×10−8 the hazard ratio 
reduced, but remained significant (Table 4). Next we calculated weighted and 
unweighted GRS and found similar associations with all-cause mortality (Table 4). 
The Kaplan-Meier failure curves for all-cause mortality are shown in Supplementary 
Figure 5. There was no specific cause of death driving the association 
(Supplementary Table 6). We extrapolated a relative risk of 1.20 to life expectancy 
using the National Life Tables of the United Kingdom and estimated a reduction of 
2.9 years for males and 2.6 years for females per 5 bpm increase in resting heart 
rate. 
  
A conceptual figure of the potential explanations of the observed association 
between genetic variants of heart rate and outcome is provided as Supplementary 
Figure 6. We performed several analyses to test for pleiotropic effects, identify 
confounders and mediators. First, we ruled out the possibility that extreme 
associations drive the genetic association with all-cause mortality by repeating the 
meta-analysis without the 12 genetic variants that each showed an association with 
mortality at P<0.05 (Table 4). Second, we adjusted for resting heart rate in the Cox 
regression model predicting all-cause mortality. The association of the genetic 
variants with all-cause mortality was abolished suggesting the genetic association is 
mediated via resting heart rate (Table 4). Next, we adjusted for covariates observed 
to be associated with identified genetic variants in UK Biobank (Table 4). Introducing 
baseline body-mass index, diastolic blood pressure, hypertension, diabetes, active 
smoking, history of heart failure, supraventricular tachycardias, myocardial infarction, 
device implantation, beta-blockers and calcium channel-blockers did not affect the 
association between the genetic variants for heart rate and all-cause mortality (Table 
4). Also when we excluded all genetic variants that individually showed nominal 
association (P<0.05) with any of the significant variables in Table 3, the association 
between the genetic variants for heart rate and all-cause mortality remained 
significant. Next we considered potential confounders of variables not currently 
available in the UK Biobank cohort and performed multivariable Mendelian 
randomization to adjust for lipids (LDL, HDL, Total Cholesterol, Triglycerides) and 
red blood cell (RBC, PCV, MCV, and Hb) variables. The adjustments did not 
attenuate the association of the heart rate genetic variants with all-cause mortality 
(Table 4). The results of the MR-Egger method confirmed the absence of evidence 
for directional (unbalanced) pleiotropy (Table 4). Also when using genetic variant 
coefficients derived from the associations with resting heart rate when restricted to 
healthy individuals (Table 1) the prediction of all-cause mortality remained similar 
(Table 4) further supporting the notion that underlying diseases or heart-rate 
lowering medication has not confounded our observation. Also when using genetic 
variant coefficients estimated in in the replication sample the association with all-
cause mortality persisted. When extrapolating the estimates from our sensitivity 
analyses, (ranging from 1.11 to 1.29 (Table 4)), this would translate to a reduction in 
life expectancy for males between 1.9 up to 4.1 years and females 1.8 up to 3.7 
years per 5 bpm increase in resting heart rate. 
 
At 19 of our 64 loci the sentinel genetic variant or a genetic variant in LD (r2 >0.8) 
have reported GWAS associations. These include: lipid, metabolic and blood 
pressure related traits (Supplementary Table 7). Our 64 loci were highly enriched 
for deoxyribonuclease I (DNase I) hypersensitive sites, marking transcriptionally 
active regions of the genome in human fetal heart tissue (Figure 2a). Enrichment 
testing of expression in 209 tissue and cell types identified cardiovascular tissues 
and the adrenal gland to be the most relevant for our association findings (Figure 
2b, Supplementary Table 8). Across the 64 loci, 1,668 annotated genes are located 
within 1 Mb of all the sentinel genetic variants. Based on proximity, the presence of 
non-synonymous genetic variants in high linkage disequilibrium (LD), cis-expression 
quantitative trait loci (eQTL) and Data-driven Expression-Prioritized Integration for 
Complex Traits (DEPICT)24 analyses we prioritized 102 potential candidate genes at 
our 64 loci (Supplementary Note, Supplementary Tables 9-11). A systematic 
search of our 102 candidate genes in Online Mendelian Inheritance in Man (OMIM) 
identified several Mendelian diseases with cardiac phenotypes. These were related 
to cardiomyopathies (TTN, DES, SCN5A, , PLN, MYH6, MYH7, SPEG), Brugada 
syndrome (SCN5A, CACNA1C, HCN4), Long QT (SCN5A, KCNJ5, ALG10), 
arrhythmias (SCN5A, HCN4, CACNA1D, MYH6) and congenital heart disease 
(NKX2-5, PLN, TBX20, MYH6, MYH7). The DEPICT tool identified 622 significantly 
(FDR<5%) enriched gene sets (Supplementary Tables 12-13). We clustered them 
on the basis of the correlation between scores for all genes (Supplementary Note) 
resulting in 74 gene sets relevant to cardiac biology (Supplementary Figure 7).  
This work highlights the unprecedented opportunities provided by large scale 
projects such as UK Biobank, the 100,000 genomes25, and the Precision Medicine 
Initiative26 to discover novel genetic associations and to study links with outcomes 
and mortality. In this GWAS and replication study, performed in 265,046 individuals, 
we found 46 novel genetic loci associated with resting heart rate increasing the total 
number of heart rate loci to 6723. Several epidemiologic studies have reported an 
association between higher resting heart rate and increased mortality from both 
cardiovascular and non-cardiovascular causes3-8. In all of these studies, this 
association is potentially confounded by differences in demographics and 
physiological characteristics such as body-mass index, smoking, alcohol 
consumption and blood pressure. Also data from intervention trials do not provide a 
consistent link between heart rate reduction and improvement of clinical outcomes. 
Selective sinus-node inhibition with ivabradine has beneficial effects on outcomes in 
patients with chronic heart failure21 but did not improve outcomes in patients with 
CAD20.  
In the present work we show that genetic variants associated with higher 
resting heart rate confer a risk for all-cause mortality. We studied the strength of 
these genetic variants with mortality and studied the role of heart rate in comparison 
of other, potential confounding variables closely associated with heart rate. The 
identified genetic variants associated with heart rate were also associated with 
potential measured (body mass index, systolic and diastolic blood pressure, 
hypertension, smoking, supraventricular tachycardia, device implantation,) and 
unmeasured confounders. However, also our analyses adjusting for covariates, 
allowing genetic variants to have pleiotropic effects, removing genetic variants 
associated with other traits, or using estimates derived from healthy participants and 
130,795 independent participants consistently suggest that heart rate is linked to 
mortality, and by extension life-expectancy. Indeed, only heart rate itself attenuated 
the association of the genetic variants with the outcome to the null. This leaves two 
likely possibilities. Either the genetic variants exert their effect on mortality directly 
via heart rate as a mediator or, alternatively, the genetic variants share underlying 
biology resulting in both increased heart rate as well as increased mortality risk. 
While direct specific intervention (sinus node inhibition) on heart rate does not 
consistently result in reduction in mortality20,21,27 we hypothesize the association 
originates from a shared biology not targeted by sinus node inhibition. This could 
involve basic cellular biology behind heart rate and possibly involve vulnerability to 
cardiac arrhythmias causing (sudden) death which might contribute to all 
classifications of death and might eventually be relevant for a plethora of also non-
cardiac diseases and conditions. This theory can be supported by the identification 
of predominant cardiac candidate genes at the identified loci and the co-localization 
of DNase hypersensitivity sites in cardiac tissue. However, also alternative 
speculations involving basic metabolic rate, energetics, free radicals, could result in 
cumulative general damage and affect life span28.  
In addition to an interpretation of causation, there are several other limitations 
of our study that are important to acknowledge. Although recent studies29,30 and 
empirical estimates on the UK10K31 and 1000 Genomes project32 support the use of 
a genome-wide significant threshold at the level of P<5.0×10−8, the adequacy of this 
value for UK Biobank has not been fully investigated. In addition, among the loci 
identified, a number of candidate genes have a known function relevant for cardiac 
conditions however, for none of the genes have we proven it is the mechanism for 
the association with heart rate. Our findings are based on statistical analyses of large 
datasets and do not include experimental validation of each locus to identify the 
underlying biological mechanisms. As with all bioinformatics analyses, the results 
should be interpreted as hypothesis-generating and requiring wet lab validation. In 
addition, the candidate gene list only provides a first interpretation using arbitrarily 
defined guidelines used in the GWAS community to suggest genes for further 
evaluation. Also heart rate is a complex trait and the principal reason for genes to be 
associated does not necessarily imply a role via the cardiac pacemaker or sinus 
node function. Due to the relative short follow-up currently available and limited 
number of events our analyses were focused on all-cause mortality and a crude 
subdivision according to ICD-10 chapters. Based on gene and pathway analyses 
differences in death due to the ICD chapter “circulatory system” might be expected 
but this was not observed. The reason remains speculative but it might be due to 
heterogenic causes of death within each chapter and also deaths in other chapters 
might be influenced by the heart but not attributed to it. When more subjects are 
genotyped and long-term follow-up becomes available, future analyses may allow 
further differentiation within each ICD-10 chapter to study associations of resting 
heart rate with specific causes of deaths. 
In conclusion, in this GWAS, we have identified 46 novel loci associated with 
resting heart rate. The identified loci influencing resting heart rate are also implicated 
in overall mortality (and consequently life expectancy) and therefore warrant further 
research into the underlying mechanisms. 
 
Data Availability Statement 
The GWAS discovery data that support the findings of this study are available at, 
http://www.cardiomics.net. 
 
Acknowledgments 
This project is supported by the Netherlands organization for health research and 
development (ZonMw grant 90.700.441). S.B is supported by the Wellcome Trust 
(grant number 100114). P.B.M. wishes to acknowledge support from the NIHR 
Cardiovascular Biomedical Research Unit at Barts and The London, Queen Mary 
University of London, UK. N.V. is supported by ICIN-NHI and Marie Sklodowska-
Curie GF (grant number 661395). This research has been conducted using the UK 
Biobank Resource. 
 
Author Contributions 
Participant recruitment, characterization and data generation: D.A.H., K.S., D.F.G., 
D.J.v.V., P.v.d.H., Data quality control and analysis: (UKBiobank) R.N.E., Y.H., 
(23andMe) D.A.H.; (deCODE) K.S., D.F.G.; (LifeLines) R.N.E., N.V., P.v.d.H.; 
(Prevend) R.N.E., N.V., P.v.d.H., Statistical analysis review: R.N.E., S.B., D.F.G., 
P.B.M., N.V., P.v.d.H., Central data analysis: R.N.E., Y.H., N.V., Supervision of the 
project: P.v.d.H., Draft of first version of the manuscript: R.N.E., P.v.d.H.. All authors 
critically reviewed and approved the final version of the manuscript. 
 
Conflict of Interest 
None declared.  
References 
1. Schmidt-Nielsen, K. Animal Physiology: Adaptation and Environment. New 
York: Cambridge University press, 133 (1975). 
2. Levine, H.J. Rest heart rate and life expectancy. J Am Coll Cardiol 30, 1104-6 
(1997). 
3. Dyer, A.R. et al. Heart rate as a prognostic factor for coronary heart disease 
and mortality: findings in three Chicago epidemiologic studies. Am J 
Epidemiol 112, 736-49 (1980). 
4. Kannel, W.B., Kannel, C., Paffenbarger, R.S., Jr. & Cupples, L.A. Heart rate 
and cardiovascular mortality: the Framingham Study. Am Heart J 113, 1489-
94 (1987). 
5. Gillum, R.F., Makuc, D.M. & Feldman, J.J. Pulse rate, coronary heart disease, 
and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 121, 
172-7 (1991). 
6. Greenland, P. et al. Resting heart rate is a risk factor for cardiovascular and 
noncardiovascular mortality: the Chicago Heart Association Detection Project 
in Industry. Am J Epidemiol 149, 853-62 (1999). 
7. Kristal-Boneh, E., Silber, H., Harari, G. & Froom, P. The association of resting 
heart rate with cardiovascular, cancer and all-cause mortality. Eight year 
follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 
21, 116-24 (2000). 
8. Reunanen, A. et al. Heart rate and mortality. J Intern Med 247, 231-9 (2000). 
9. Kolloch, R. et al. Impact of resting heart rate on outcomes in hypertensive 
patients with coronary artery disease: findings from the INternational 
VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29, 1327-34 (2008). 
10. Diaz, A., Bourassa, M.G., Guertin, M.C. & Tardif, J.C. Long-term prognostic 
value of resting heart rate in patients with suspected or proven coronary artery 
disease. Eur Heart J 26, 967-74 (2005). 
11. Bohm, M. et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the 
association between heart rate and outcomes in a randomised placebo-
controlled trial. Lancet 376, 886-94 (2010). 
12. Grassi, G. et al. Heart rate as marker of sympathetic activity. J Hypertens 16, 
1635-9 (1998). 
13. Bohm, M., Reil, J.C., Deedwania, P., Kim, J.B. & Borer, J.S. Resting heart 
rate: risk indicator and emerging risk factor in cardiovascular disease. Am J 
Med 128, 219-28 (2015). 
14. Aladin, A.I. et al. The Association of Resting Heart Rate and Incident 
Hypertension: The Henry Ford Hospital Exercise Testing (FIT) Project. Am J 
Hypertens (2015). 
15. Jiang, X. et al. Metabolic syndrome is associated with and predicted by 
resting heart rate: a cross-sectional and longitudinal study. Heart 101, 44-9 
(2015). 
16. Caetano, J. & Delgado Alves, J. Heart rate and cardiovascular protection. Eur 
J Intern Med 26, 217-22 (2015). 
17. Bangalore, S. et al. beta-Blocker use and clinical outcomes in stable 
outpatients with and without coronary artery disease. JAMA 308, 1340-9 
(2012). 
18. Messerli, F.H., Grossman, E. & Goldbourt, U. Are beta-blockers efficacious as 
first-line therapy for hypertension in the elderly? A systematic review. JAMA 
279, 1903-7 (1998). 
19. Van Gelder, I.C. et al. Lenient versus strict rate control in patients with atrial 
fibrillation. N Engl J Med 362, 1363-73 (2010). 
20. Fox, K. et al. Ivabradine in stable coronary artery disease without clinical heart 
failure. N Engl J Med 371, 1091-9 (2014). 
21. Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): 
a randomised placebo-controlled study. Lancet 376, 875-85 (2010). 
22. Sudlow, C. et al. UK biobank: an open access resource for identifying the 
causes of a wide range of complex diseases of middle and old age. PLoS 
Med 12, e1001779 (2015). 
23. den Hoed, M. et al. Identification of heart rate-associated loci and their effects 
on cardiac conduction and rhythm disorders. Nat Genet 45, 621-31 (2013). 
24. Pers, T.H. et al. Biological interpretation of genome-wide association studies 
using predicted gene functions. Nat Commun 6, 5890 (2015). 
25. Siva, N. UK gears up to decode 100,000 genomes from NHS patients. Lancet 
385, 103-4 (2015). 
26. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N Engl J 
Med 372, 793-5 (2015). 
27. Fox, K., Ford, I., Steg, P.G., Tendera, M. & Ferrari, R. Ivabradine for patients 
with stable coronary artery disease and left-ventricular systolic dysfunction 
(BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 
372, 807-16 (2008). 
28. Azbel, M. Universal biological scaling and mortality. Proc Natl Acad Sci U S A 
91, 12453-7 (1994). 
29. Davies, G. et al. Genome-wide association study of cognitive functions and 
educational attainment in UK Biobank (N=112 151). Mol Psychiatry 21, 758-
67 (2016). 
30. Lane, J.M. et al. Genome-wide association analysis identifies novel loci for 
chronotype in 100,420 individuals from the UK Biobank. Nat Commun 7, 
10889 (2016). 
31. Xu, C. et al. Estimating genome-wide significance for whole-genome 
sequencing studies. Genet Epidemiol 38, 281-90 (2014). 
32. Kanai, M., Tanaka, T. & Okada, Y. Empirical estimation of genome-wide 
significance thresholds based on the 1000 Genomes Project data set. J Hum 
Genet (2016). 
 
Figure legends 
 
Figure 1. Genomewide –log10 P-value plot and effects for significant loci  
Genomewide –log10 P-value plots are shown for heart rate. Genetic variants within 
loci reaching genomewide significance are labeled in blue when previously identified 
and red when novel (±1Mb of lowest P-value). The dashed line indicates the 
genomewide significance threshold (P=5×10-8). Candidate genes have been 
identified by one or multiple strategies; n=nearest; c=coding, non-synonymous 
variant; e=eQTL; d=DEPICT tool. 
 
Figure 2. Biological insights (a) The 64 genomewide associated variants were 
enriched within DHSs of fetal heart tissue (N=8) specifically, suggesting that 
functionality of regulatory DNA elements may underlie some of the associations. (b) 
DEPICT identified statistically significant enrichment for 9 tissue annotations of which 
cardiovascular tissues were the most relevant for the heart rate associated loci.  
Table 1. Baseline characteristics of participants 
 
 
 
All 
(N=134,251) 
SD or 
percentage (%) 
Healthy 
Individuals 
(N=11,405) 
SD or 
percentage (%) 
Age 56.6   8.0 53.7   7.6 
Sex (Male) 63,349  47.2% 5,993  52.5% 
Body-mass index 27.5  4.8 26.3  4.0 
Resting heart rate 69.5  11.1 68.3  10.5 
Blood pressure  
 Systolic 
 Diastolic 
 
138.0  
82.3  
 
18.6 
10.1 
 
135.5  
81.6  
 
17.7 
9.8 
Ethnicity     
 Asian/ Chinese 2,478  1.8% 248  2.2% 
 Black 1,734  1.3% 173  1.5% 
 Mixed 684  0.5% 52  0.5% 
 White 127,919  95.3% 10,797  94.7% 
 Other/ undefined 1,436  1.1% 135  1.2% 
Smoking current 16,708  12.4% 1,390  8.3% 
Medical History      
 Hypertension 38,339  28.6% 0 0% 
 Diabetes 7,419  5.5% 0 0% 
 Myocardial Infarction 3,395  2.5% 0 0% 
 Heart failure 720  0.5% 0 0% 
 Atrial fibrillation / flutter 2,048  1.5% 0 0% 
 Supraventricular 
tachycardia 
425  0.3% 0 0% 
 Device implantation 399  0.3% 0 0% 
Medication   0 0% 
 Beta-blockers 9,526  7.8% 0 0% 
 Calcium channel-blockers 9,797  8.0% 0 0% 
Abbreviations;  SD, Standard Deviation. 
Table 2. Results of the newly identified loci that showed association with heart rate at genome-wide 
significance (P<5×10−8) 
   Alleles  Discovery 
(UK Biobank) 
Replication Meta-analysis  
Variant Chr. Pos.a Non-coded Coded EAF β SE P β SE P β SE P N Candidate 
Genes 
rs145358377 1 6272136 G GA 0.36 -0.29 0.04 1.69× 
10-10 
-0.182 0.077 1.78× 
10-2 
-0.259 0.039 1.94× 
10-11 
265,046 RNF207nc; 
ICMTn 
rs272564 1 45012273 A C 0.28 0.41 0.05 5.02× 
10-17 
0.271 0.058 3.30× 
10-6 
0.351 0.037 4.51× 
10-21 
265,046 RNF220n 
rs2152735 1 87893132 G A 0.33 -0.32 0.05 6.48× 
10-12 
-0.291 0.056 2.06× 
10-7 
-0.306 0.036 7.23× 
10-18 
265,046 LMO4n 
rs11454451 1 217722890 C CT 0.26 0.28 0.05 8.81× 
10-9 
0.216 0.059 2.45× 
10-4 
0.256 0.038 1.29× 
10-11 
265,046 GPATCH2n 
rs1260326 2 27730940 T C 0.39 -0.29 0.04 4.54× 
10-11 
-0.256 0.054 1.75× 
10-6 
-0.275 0.034 4.29× 
10-16 
265,046 GCKRnc 
rs12713404 2 60006705 G T 0.38 -0.26 0.05 1.75× 
10-8 
-0.120 0.053 2.42× 
10-2 
-0.199 0.035 9.33× 
10-9 
265,046 BCL11An 
rs564190295 2 175547672 G GCCGCC 
GCCCCC 
0.15 -0.36 0.06 1.00× 
10-8 
-0.344 0.142 1.57× 
10-2 
-0.355 0.057 4.95× 
10-10 
197,184 WIPF1n 
rs907683 2 220299541 G T 0.43 -0.35 0.04 1.27× 
10-15 
-0.296 0.061 1.10× 
10-6 
-0.334 0.036 1.02× 
10-20 
265,046 SPEGnd; DESn 
rs4608502 2 228134155 T C 0.33 0.27 0.05 5.44× 
10-9 
0.221 0.055 6.02× 
10-5 
0.249 0.035 1.85× 
10-12 
265,046 COL4A3n 
rs7641050 3 48762507 T C 0.22 0.31 0.05 2.39× 
10-9 
0.186 0.062 2.57× 
10-3 
0.257 0.040 7.15× 
10-11 
265,046 IP6K2n; 
DALRD3c;  
KLHDC8Bed; 
P4HTMe; 
 AMTe; 
QRICH1ed 
rs3749237 3 49770032 G A 0.32 0.33 0.05 5.18× 
10-13 
0.150 0.056 7.40× 
10-3 
0.258 0.035 3.09× 
10-13 
265,046 IP6K1n; 
GMPPBn;  
FAM212Ad; 
DAG1d;  
KLHDC8Bed; 
LAMB2d;  
PRKAR2Ad; 
QRICH1ed 
rs2358740 3 53455569 G T 0.32 -0.26 0.05 9.24× 
10-9 
-0.128 0.055 2.03× 
10-2 
-0.208 0.035 3.58× 
10-9 
265,046 CACNA1Dn 
rs1483890 3 69410725 A G 0.30 0.29 0.05 3.56× 
10-10 
0.272 0.056 1.38× 
10-6 
0.284 0.036 2.54× 
10-15 
265,046 FRMD4Bn 
rs11920570 3 122090102 G A 0.26 0.37 0.05 3.91× 
10-14 
0.127 0.058 2.75× 
10-2 
0.268 0.037 5.18× 
10-13 
265,046 CCDC58n 
rs12501032 4 23951018 C G 0.31 0.29 0.05 3.65× 
10-10 
0.278 0.057 9.80× 
10-7 
0.288 0.036 1.83× 
10-15 
265,046 PPARGC1An 
rs6845865 4 148974602 T C 0.16 -0.38 0.06 3.16× 
10-11 
-0.281 0.072 9.07× 
10-5 
-0.342 0.045 2.25× 
10-14 
265,046 ARHGAP10nd; 
EDNRAd 
rs13165531 5 30888583 A T 0.42 -0.26 0.04 2.75× 
10-9 
-0.166 0.053 1.65× 
10-3 
-0.221 0.034 4.31× 
10-11 
265,046 CDH6n 
rs1468333# 5 137552970 T C 0.63 -0.27 0.04 1.23× 
10-9 
-0.233 0.054 1.52× 
10-5 
-0.255 0.034 9.53× 
10-14 
265,046 CDC23n 
rs236349 6 36820565 A G 0.34 0.29 0.05 2.46× 
10-10 
0.273 0.055 8.11× 
10-7 
0.281 0.035 1.01× 
10-15 
265,046 PPIL1ne 
rs58437978 7 35258277 T C 0.50 -0.27 0.04 2.26× 
10-10 
-0.183 0.057 1.32× 
10-3 
-0.240 0.034 2.61× 
10-12 
265,046 TBX20n 
rs41748 7 116446573 T G 0.45 -0.24 0.04 1.90× -0.120 0.052 2.23× -0.193 0.033 7.14× 265,046 METn 
10-8 10-2 10-9 
rs11563648 7 126970046 G C 0.27 -0.31 0.05 1.79× 
10-10 
-0.121 0.058 3.74× 
10-2 
-0.231 0.037 4.42× 
10-10 
265,046 ZNF800n 
rs138186803 7 130965408 AT A 0.41 -0.30 0.04 7.81× 
10-12 
-0.550 0.107 2.70× 
10-7 
-0.333 0.040 1.27× 
10-16 
197,184 MKLN1n 
rs56233017 8 144981488 G A 0.04 -0.68 0.11 8.41× 
10-11 
-0.637 0.135 2.49× 
10-6 
-0.666 0.083 1.09× 
10-15 
265,046 PLECn 
rs10739663 9 128278739 A G 0.45 -0.29 0.04 1.20× 
10-11 
-0.229 0.052 1.05× 
10-5 
-0.266 0.033 9.62× 
10-16 
265,046 MAPKAP1ne 
rs12576326 11 44980383 A G 0.34 0.27 0.05 1.40× 
10-9 
0.219 0.058 1.57× 
10-4 
0.253 0.036 1.20× 
10-12 
265,046 TP53I11n 
rs75190942 11 128764571 C A 0.09 -0.50 0.08 4.72× 
10-11 
-0.498 0.099 4.90× 
10-7 
-0.496 0.060 1.19× 
10-16 
265,046 KCNJ5nd; 
C11orf45n 
rs2283274 12 2184466 G C 0.18 -0.43 0.06 6.53× 
10-14 
-0.371 0.071 1.58× 
10-7 
-0.405 0.044 7.21× 
10-20 
265,046 CACNA1Cn 
rs10841486 12 20472202 T C 0.22 -0.30 0.05 8.65× 
10-9 
-0.148 0.063 1.89× 
10-2 
-0.238 0.040 2.98× 
10-9 
265,046 PDE3And 
rs1050288 12 27955296 C T 0.34 -0.26 0.05 1.70× 
10-8 
-0.142 0.057 1.36× 
10-2 
-0.213 0.036 2.74× 
10-9 
265,046 KLHL42n 
rs10880689$ 12 37930102 A G 0.60 0.20 0.04 4.65× 
10-6 
0.221 0.054 3.91× 
10-5 
0.208 0.034 8.10× 
10-10 
265,046 ALG10Bn 
rs867400 12 64976850 T C 0.43 0.30 0.04 7.80× 
10-12 
0.301 0.053 1.05× 
10-8 
0.298 0.033 4.58× 
10-19 
265,046 RASSF3nd 
rs12579753 12 82219376 C T 0.23 -0.28 0.05 3.92× 
10-8 
-0.193 0.062 1.74× 
10-3 
-0.246 0.039 4.81× 
10-10 
265,046 PPFIA2ne 
rs12889267 14 21542766 A G 0.16 0.41 0.06 7.78× 
10-13 
0.421 0.073 7.89× 
10-9 
0.416 0.045 3.61× 
10-20 
265,046 NDRG2n; 
ARHGEF40ncd; 
 ZNF219d 
rs17180489 14 72885471 G C 0.14 -0.52 0.06 3.14× -0.370 0.132 5.01× -0.490 0.055 9.15× 214,007 RGS6n 
10-17 10-3 10-19 
rs1549118 14 78379684 C T 0.28 0.26 0.05 4.59× 
10-8 
0.113 0.057 4.80× 
10-2 
0.200 0.037 4.67× 
10-8 
265,046 ADCK1n 
rs4900069 14 91583373 A C 0.37 0.25 0.04 1.55× 
10-8 
0.125 0.054 2.14× 
10-2 
0.200 0.034 5.38× 
10-9 
265,046 C14orf159n 
rs3915499 16 15910743 G A 0.32 0.32 0.05 5.94× 
10-12 
0.284 0.056 3.72× 
10-7 
0.303 0.035 1.24× 
10-17 
265,046 MYH11nd 
rs7194801 16 65286870 T C 0.43 -0.33 0.04 6.78× 
10-14 
-0.240 0.052 4.49× 
10-6 
-0.291 0.033 3.58× 
10-18 
265,046 CDH11n 
rs79121763 17 15195279 C T 0.09 -0.52 0.08 1.53× 
10-11 
-0.376 0.110 6.59× 
10-4 
-0.471 0.063 7.17× 
10-14 
265,046 TEKT3n; 
PMP22d 
rs11083258 18 25766218 A C 0.17 -0.33 0.06 7.25× 
10-9 
-0.192 0.071 6.96× 
10-3 
-0.276 0.045 5.51× 
10-10 
265,046 CDH2nd 
rs61735998 18 34289285 G T 0.02 -0.98 0.14 1.39× 
10-12 
-0.593 0.176 7.74× 
10-4 
-0.834 0.109 2.06× 
10-14 
265,046 FHOD3ncd 
rs16974196 19 40833470 G A 0.32 0.26 0.05 1.36× 
10-8 
0.217 0.057 1.55× 
10-4 
0.244 0.036 1.11× 
10-11 
265,046 C19orf47nd; 
MAP3K10e 
rs12721051 19 45422160 C G 0.18 -0.32 0.06 1.40× 
10-8 
-0.241 0.071 6.45× 
10-4 
-0.287 0.044 5.23× 
10-11 
265,046 APOEn; 
APOC1n;  
PVRL2d 
rs17265513 20 39832628 T C 0.19 0.30 0.05 2.36× 
10-8 
0.146 0.066 2.78× 
10-2 
0.240 0.042 1.12× 
10-8 
265,046 ZHX3nc; 
EMILIN3d 
rs2076028 22 39150450 G A 0.29 -0.36 0.05 1.81× 
10-14 
-0.197 0.057 5.49× 
10-4 
-0.295 0.036 5.45× 
10-16 
265,046 SUN2n; 
CBY1e;  
FAM227Ae; 
JOSD1e;  
TOMM22e; 
DDX17d;  
GTPBP1d 
Abbreviations;  EAF, Effect Allele Frequency; Chr, Chromosome; Pos, Position; β, Beta; SE, Standard Error. 
aPositions are according to 1000 Genomes Phase 3, and allele coding is based on the positive strand. 
Candidate genes have been identified by one or multiple strategies; n=nearest; c=coding, non-synonymous 
variant; e=eQTL; d=DEPICT tool. #Proxy of rs35284930, R2=0.85. $Proxy of rs11183443, R2=0.92.  
Table 3. Association between genetically determined heart rate and cardiovascular profile using a weighted GRS  
 Participants 
(N= 134,251) 
Percentage (%) Estimated 
Association* 
95% CI P value 
Body-mass index 134,251  100.0% 0.14  0.08 to 0.20 2.24×10-6 
Blood pressure  
 Systolic 
 Diastolic 
 
134,217  
134,217 
 
99.0% 
99.0% 
 
-0.51  
0.78  
 
-0.30 to -0.72 
0.66 to 0.90 
 
2.55×10-6 
1.32×10-36 
Hypertension 39,996  29.8% 1.04  1.01 to 1.07 4.41×10-3 
Diabetes 7,857  5.9% 1.04  0.99 to 1.09 0.16 
Smoking current 16,708  12.4% 1.07  1.03 to 1.11 2.98×10-4 
Myocardial Infarction 3,848  2.9% 0.99  0.92 to 1.07 0.80 
Heart failure 1,131  0.8% 1.14  0.99 to 1.31 0.06 
Atrial fibrillation / flutter 2,780  2.1% 1.01  0.93 to 1.10 0.79 
Supraventricular tachycardia 546  0.4% 1.28  1.05 to 1.56 0.02 
Device implantation 482  0.4% 0.80  0.66 to 0.96 0.02 
Medication      
 Beta-blockers 9,526  7.8% 1.04  0.99 to 1.09 0.10 
 Calcium channel-blockers 9,797 8.0% 1.02  0.98 to 1.07 0.34 
 
* The effect estimates with 95% Confidence Interval (CI) estimated using weighted GRS (per 5 bpm increase in resting 
heart rate) are shown as odds ratios for categorical variables (hypertension, diabetes, smoking current, myocardial 
infarction, heart failure, atrial fibrillation / flutter, supraventricular tachycardia, device implantation, beta-blockers and 
calcium-channel blockers) and β estimates for quantitative variables (body-mass index, systolic and diastolic blood 
pressure).
Table 4. Association between genetically determined resting heart rate and all-cause mortality 
Association with mortality Number of 
GVs 
Estimated Association 
HR*  
95% CI P value 
 
Standard MR with all 
 GVs (P<10-2) 1980 1.19 1.14 to 1.23 3.77×10-19 
 GVs (P<10-3) 1739 1.19 1.14 to 1.23 5.91×10-19 
  GVs (P<10-4) 848 1.19 1.13 to 1.24 1.13×10-11 
 GVs (P<10-5)  272 1.20 1.11 to 1.28 8.20×10-7 
 GVs (P<10-6) 121 1.14 1.05 to 1.25 3.33×10-3 
 GVs (P<10-7) 82 1.13 1.02 to 1.25 1.46×10-2 
 GVs (P<5×10-8)  76 1.11 1.00 to 1.22 5.01×10-2 
 GVs (P<10-5) excluding those associated (P<0.05) mortality  260 1.15 1.07 to 1.24 1.53×10-4 
 GVs (P<10-5) with adj. for resting heart rate 272 1.02 0.95 to 1.09 0.65 
 GVs (P<10-5) with adj. for covariates# 272 1.18 1.10 to 1.27 4.69×10-6 
 GVs (P<10-5) excluding those associated (P<0.05) with variable# 55 1.29 1.09 to 1.53 3.66×10-3 
   GVs (P<10-5) betas estimated on 11,405 healthy individuals 272 1.14 1.07 to 1.23 6.85×10-5 
 GVs (P<10-5) betas estimated on 130,795 individuals from replication 269 1.11 1.01 to 1.22 2.70×10-2 
GRS weighted GVs (P<10-5) 272 1.18 1.10 to 1.26 3.22×10-6 
GRS unweighted GVs (P<10-5) 272 1.05 1.03 to 1.08 4.37×10-5 
Multivariable MR with adj. for covariates# 272 1.26 1.13 to 1.42 8.03×10-5 
Multivariable MR with adj. for lipid covariates$ 209 1.18 1.09 to 1.27 1.99×10-5 
Multivariable MR with adj. for red blood cell covariates@ 173 1.18 1.09 to 1.28 4.53×10-5 
*Hazard ratio (HR) with 95% Confidence Interval (CI) estimated with standard Mendelian Randomization (MR) and 
weighted Genetic Risk Score (GRS) per 5 bpm and for unweighted GRS per 5 summed risk alleles; Genetic Variants 
(GVs); Adjustment (adj.); #Baseline body-mass index, systolic and diastolic blood pressure, hypertension, diabetes, active 
smoking, and a history of myocardial infarction, heart failure, atrial fibrillation / flutter, supraventricular tachycardias, 
myocardial infarction, device implantation, beta-blockers and calcium channel-blockers; $Lipid covariates including; Low 
Density Lipoprotein (LDL), High Density Lipoproteins (HDL) Total Cholesterol and Triglycerides; @Red blood cell 
covariates including; Red Blood Cell Count  (RBC), Packed Cell Volume (PCV), Mean Corpuscular Volume (MCV) and 
Hemoglobin count (Hb). 
MR-Egger method (P<10-5) 272 1.21 1.05 to 1.40 8.00×10-3 
Online Methods 
Populations. 
Discovery: To identify genetic variants associated with resting heart rate we analyzed 
134,251 participants from the UK Biobank. The UK Biobank recruited persons aged 40 - 
69 years who were registered with a general medical practitioner within the UK National 
Health Service (NHS). In total, the study recruited 503,325 individuals between 2006 
and 2010. The study has approval from the North West Multi-centre Research Ethics 
Committee, and all participants provided informed consent. Detailed methods used by 
UK Biobank have been described elsewhere22. For sensitivity analyses we defined a 
subgroup of healthy individuals which were free of any (prevalent or incident) disease(s) 
and diagnosis and confirmed they were not using heart rate modifying medication (beta-
blockers, and calcium-channel blockers drugs (N=11,405)). 
Replication: Replication of genome wide significant lead SNPs was undertaken in the 
meta-analysed data of 130,795 individuals derived from 23andMe, deCODE, PREVEND 
and LifeLines sample collections (Supplementary Table 14). 
Ascertainment of resting heart rate. 
As detailed in the Supplementary Note, resting heart rate in UK Biobank was assessed 
by two methods: an automated reading during blood pressure measurement (in 501,340 
participants) and during arterial stiffness measurement using the pulse waveform 
obtained of the finger with an infrared sensor (in 170,790 participants). Multiple 
available measurements for one individual were averaged.  
Ascertainment of cardiovascular events and mortality. 
The prevalence and incidence of cardiovascular risk factors (Supplementary Table 
15), conditions and events in UK Biobank were captured through data collected at the 
Assessment Centre in-patient Health Episode Statistics (HES) as detailed in the 
Supplementary Note. Information on the cause of death was obtained via the National 
Health Service (NHS) Information Centre for participants from England and Wales, and 
from the NHS Central Register, Scotland for participants from Scotland. All-cause 
mortality included all deaths occurring before February 17th 2014 (or December 31st 
2012, for the participants enrolled in Scotland).  
Genotyping and Imputation. 
Genotype imputation data in UK Biobank was available for 152,249 (25%) individuals as 
of May 2015 [Interim Data Release]. In 49,923 individuals genotyping was performed as 
part of the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE; 807,411 variants) 
project and in an additional 102,326 individuals genotyping was performed on the UK 
Biobank Axiom array (Affymetrix; 820,967 variants). Imputed genotype data was 
provided by UK Biobank based on merged UK10K and 1000 Genomes Phase 3 panel 
produced by the Wellcome Trust Centre for Human Genetics resulting in 72,355,667 
single nucleotide polymorphisms, short indels and large structural variants. Quality 
control for genotyping has been performed prior to analysis and described in detail 
elsewhere33. We excluded variants with minor allele frequency of <0.001, and 
information measure <0.3 leaving 19,941,912 variants for the current analyses. 
Samples were excluded from our analyses if they had at least one related sample 
(N=17,308) based on genetic relatedness factor data, and high missingness or excess 
heterozygosity (N=480). A flow diagram of samples sizes after exclusion of participants 
is provided in Supplementary Figure 8. 
Statistical Analysis. 
A genome-wide association study (GWAS) was performed using SNPTEST with 
19,941,912 genotyped or imputed genetic variants and resting heart rate in 134,251 
individuals of UK Biobank using linear regression assuming an additive genetic model. 
Covariates included in the model were: age, age2, sex, the first 10 principal 
components, and genotyping array. Independent genetic loci were defined as 1Mb at 
either side of the genetic variant  that showed the strongest association in a given locus 
and pair-wise LD r2<0.1. The strongest associated variant (lowest P-value) within a 
locus with at least one genetic variant at P<5×10-8 was designated the sentinel genetic 
variant. Replication of these variants was undertaken in the 23andMe, deCODE, 
Prevend and LifeLines cohorts using fixed-effects meta-analysis by inverse variance 
weighting (Supplementary Table 14). An association was considered replicated if (1) 
the direction of effect was concordant, (2) the replication-P<0.025 (one-way), and (3) 
meta-P<5×10-8. For detecting secondary associations not explained by the sentinel 
genetic variant at each locus, we repeated the GWAS while including all sentinel 
genetic variants (P<5×10−8) as covariates in a conditional analysis. Potential modifier 
effects of gender, β-adrenergic receptor-blocking agent (beta-blockers), and calcium-
channels blockers drugs on resting heart rate were assessed by an interaction test 
(Bonferroni adjusted for the number (n) of tests (P<0.05/n)).  
We used genetic variants as instrumental variables to study the relationship of 
resting heart rate with outcomes (Mendelian Randomization). To this end we defined a 
larger set of independent loci at the previously specified hypothesis-generating 
threshold (P<1×10−5) in order to increase power34,35. For our main analysis we 
calculated β3 values (the putative association between resting heart rate (per 5 beats 
per minute (bpm) and outcome mediated through that variant) from the direct 
measurements of β1 (the effect size of the association between the variant and resting 
heart rate) and β2 (the effect size of the association between the variant and outcome), 
as described previously36. The value of β3 can be interpreted as the hazard ratio for 
outcome per 5 bpm increase in genetically determined resting heart rate. Inverse-
variance-weighted random-effects meta-analysis was used to combine individual β3 
estimates providing additional power to assess the overall association between 
genetically determined resting heart rate and mortality. Cochran’s Q statistic was used 
to assess heterogeneity among β3 estimates. We also created a weighted genetic risk 
score (GRS) by first multiplying for each individual the effect size of the association 
between the variant and resting heart rate (β1) with the number of alleles 0-2 of each 
genetic variant and then summing all products. An unweighted GRS was created by 
summing the number of resting heart rate-increasing alleles 0-2 of each associated 
genetic variant.  
To examine the robustness of our findings as well as the possibility of pleiotropic 
or other confounding and mediation effects we included covariates and the phenotype 
resting heart rate into the Cox regression models. We excluded all genetic variants that 
were also individually nominally associated (P<0.05) with covariates, and performed 
multivariable Mendelian randomization37 to account for variables not available in UK 
Biobank, and used the MR-Egger regression method to test for evidence of pleiotropy38 
(details provided in Supplementary Note and Supplementary Figures 9-10). As an 
alternative strategy to exclude confounding due to prevalent disease or medication use, 
we estimated the associations of each genetic variant with resting heart rate (β1) in the 
subgroup of 11,405 healthy individuals (defined above) to calculate the hazard ratio for 
outcome. We estimated the impact on life expectancy using the National Life Tables of 
the United Kingdom provided by the Office of National Statistics (ONS; 
www.ons.gov.uk) of 2011-2013 separately for males and females (Supplementary 
Note). 
Details of analyses performed to gain insights in the biological pathways and 
tissues underlying the genome-wide significant loci are provided in the Supplementary 
Note. 
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